Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

daratumumab

Drug and asset intelligence for daratumumab with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

JNJ-79635322 →

Recent signals(2)

CompetitiveJuly 23, 2026

AbbVie Initiates Study on Surzetoclax for Relapsed/Refractory Multiple Myeloma

AbbVie is conducting a study to evaluate the safety and efficacy of surzetoclax in combination with other agents for relapsed/refractory multiple myeloma.

ClinicalJuly 22, 2026

JNJ-79635322 Dose Escalation Study in Multiple Myeloma Shows Promising Combinations

The study aims to establish recommended Phase 2 doses for JNJ-79635322 in combination with daratumumab and other agents.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Daratumumab

July 13, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Multiple Myeloma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.